Healthcare provider profile · identity verified

Shanthi Subbiah, MD

Internal Medicine · LAUREL SPRINGS, NJ · NPI 1104897370

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	335	53
Eliquis	Apixaban	323	28
Levothyroxine Sodium	Levothyroxine Sodium	224	37
Furosemide	Furosemide	185	40
Pantoprazole Sodium	Pantoprazole Sodium	180	42
Gabapentin	Gabapentin	172	30
Amlodipine Besylate	Amlodipine Besylate	156	34
Metoprolol Succinate	Metoprolol Succinate	147	33
Potassium Chloride	Potassium Chloride	139	25
Tamsulosin Hcl	Tamsulosin Hcl	113	26
Metoprolol Tartrate	Metoprolol Tartrate	106	19
Mirtazapine	Mirtazapine	106	17
Sertraline Hcl	Sertraline Hcl	97	23
Lisinopril	Lisinopril	89	16
Clopidogrel	Clopidogrel Bisulfate	79	14
Metformin Hcl	Metformin Hcl	77	16
Divalproex Sodium	Divalproex Sodium	75	suppressed
Levetiracetam	Levetiracetam	73	12
Losartan Potassium	Losartan Potassium	73	suppressed
Donepezil Hcl	Donepezil Hcl	67	11
Omeprazole	Omeprazole	66	suppressed
Albuterol Sulfate	Albuterol Sulfate	62	15
Escitalopram Oxalate	Escitalopram Oxalate	59	13
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	59	11
Carvedilol	Carvedilol	55	12
Hydralazine Hcl	Hydralazine Hcl	54	13
Trazodone Hcl	Trazodone Hcl	51	11
Milrinone Lactate	Milrinone Lactate	44	suppressed
Ondansetron Hcl	Ondansetron Hcl	43	19
Rosuvastatin Calcium	Rosuvastatin Calcium	43	suppressed
Allopurinol	Allopurinol	42	suppressed
Warfarin Sodium	Warfarin Sodium	42	suppressed
Xarelto	Rivaroxaban	42	suppressed
Buspirone Hcl	Buspirone Hcl	41	suppressed
Montelukast Sodium	Montelukast Sodium	40	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	37	suppressed
Nuplazid	Pimavanserin Tartrate	35	suppressed
Latanoprost	Latanoprost	34	suppressed
Acetic Acid	Acetic Acid	33	16
Glimepiride	Glimepiride	33	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	33	suppressed
Jardiance	Empagliflozin	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Memantine Hcl	Memantine Hcl	30	suppressed
Midodrine Hcl	Midodrine Hcl	30	suppressed
Oxcarbazepine	Oxcarbazepine	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	29	suppressed
Fluticasone Propionate	Fluticasone Propionate	28	suppressed
Incruse Ellipta	Umeclidinium Bromide	27	suppressed
Amiloride Hcl	Amiloride Hcl	26	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	25	suppressed
Bumetanide	Bumetanide	24	suppressed
Tradjenta	Linagliptin	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Benztropine Mesylate	Benztropine Mesylate	22	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	22	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	22	suppressed
Sucralfate	Sucralfate	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	21	suppressed
Famotidine	Famotidine	21	suppressed
Labetalol Hcl	Labetalol Hcl	21	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	20	suppressed
Restasis	Cyclosporine	20	suppressed
Risperidone	Risperidone	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Calcitriol	Calcitriol	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Milrinone In 5% Dextrose	Milrinone Lactate/D5w	18	suppressed
Simvastatin	Simvastatin	18	suppressed
Amiodarone Hcl	Amiodarone Hcl	17	suppressed
Auryxia	Ferric Citrate	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Desmopressin Acetate	Desmopressin Acetate	17	suppressed
Procrit	Epoetin Alfa	17	suppressed
Torsemide	Torsemide	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Ammonium Lactate	Ammonium Lactate	15	11
Metolazone	Metolazone	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Timolol Maleate	Timolol Maleate	15	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	14	suppressed
Erythromycin	Erythromycin Base	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	14	suppressed
Valsartan	Valsartan	14	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	13	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Primidone	Primidone	13	suppressed
Santyl	Collagenase Clostridium Hist.	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Carbamazepine Er	Carbamazepine	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Divalproex Sodium Er	Divalproex Sodium	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	12	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Prednisone	Prednisone	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error